Matthias Hackl, CEO/CSO of TAmiRNA, visited Japan between November 11th and 18th to join Summit Pharmaceutical international to introduce TAmiRNA to 12 medium- and large-size pharmaceutical companies. Matthias presented information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs. In addition, Matthias joined a seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products” organized by the local partner Summit Pharmaceutical International. In his talk, Matthias explained to >70 representatives from Japanese Universities and Pharmaceutical industry TAmiRNA’s the advantages of full molecular characterization of exosomes and extracellular vesicles (EVs) to determine EV composition, consistency, and mode-of-action.
TAmiRNA Scientific Consultant Magdalena Mecking is attending the Extracellular Vesicles Forum on Oct 10th – 11th in Cambridge. Stop by one of her posters and learn more about how TAmiRNA’s service may benefit your EV project! Reach out to Magdalena directly and discuss our latest developments and how TAmiRNA's services can assist your business!
TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Boston next week to speak about how cell-free RNA biomarkers can be incorporated in pre-clinical and clinical development to inform about drug safety, drug targeting, and drug efficacy. Reach out to Matthias directly to meet with him before or after his presentation on Thursday, Sept. 7th at 4:30 pm ET and discuss our latest developments and how TAmiRNA's services can assist your business!
TAmiRNA will be a significant contributor to the inaugural joint European meeting of the ISSX and DMDG respectively focused on xenobiotics and drug metabolics. Dr. Matthias Hackl, CEO and co-founder, will take part in the discussions of Symposium 4: ‘MicroRNAs as Biomarkers of Clinical Drug-induced Organ Injury’ (Tuesday, June 13, 1000-1200 hrs). Dr. Hackl’s presentation ‘miRNA Biomarker Development: Pitfalls and Best Practices for Discovery and Validation’ will highlight the increasing scope to apply TAmiRNA’s recently developed MicroRNA Next-Generation Sequencing Discovery (miND®) technology and associated miND® spike-ins to identify novel circulating microRNA biomarkers of CNS and other organ damage, as well as comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs). Take advantage, [...]
TAmiRNA Senior Scientist Dr. Kseniya Khamina-Kotisch will present Poster 46 ‘Identification of novel circulating MicroRNA Biomarkers of Central Nervous System Damage by absolute quantitation using a MicroRNA Next-Generation Sequencing Discovery (miND) Assay’. She will also present Poster 66: ‘Comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs) in cells, plasma, urine, and extracellular vesicles’. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's miND spike ins and services can assist your business!